Go to
- Discovered an alarming bug (or is it a 'feature'?) in the latest version of Keynote. Presentations created in V8.2 on High Sierra will still open in Keynote 6.6 on El Cap, but when resaved in 6.6 on El Cap they cannot then be opened again. Same happens to Pages files. Is this a bug or a deliberate move from Apple because El Cap is no longer.
- Some of the fastest growing chains in the restaurant industry are the ones embracing innovation throughout their operations. The Summit will help restaurant operators to be more progressive in many areas of their business to attract both investors and customers.
- With Keynote, you have all the tools you need to make an amazing presentation quickly and easily. With real-time collaboration, your whole team can work together on a presentation at the same time. Collaboration is built right in to Keynote on the Mac, iPad, iPhone and iPod touch. Keynote Live lets you present a slideshow that.
This update is recommended for all macOS Sierra users. The macOS Sierra 10.12.6 Update improves the security, stability, and compatibility of your Mac, and is recommended for all users.
This study is a rolling arm study of pembrolizumab in combination with investigational agents in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation.
Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a separate study or in the safety lead-in of this study. If an RP2D for a combination being evaluated in the safety lead-in is established from another study, then the efficacy evaluation may begin at the determined RP2D.
There will be no hypothesis testing in this study.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Small Cell Lung Carcinoma | Biological: coformulation pembrolizumab/quavonlimabDrug: lenvatinibBiological: MK-4830Biological: coformulation favezelimab/pembrolizumab | Phase 1Phase 2 |
Go to
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98) |
| Estimated Study Start Date : | August 6, 2021 |
| Estimated Primary Completion Date : | November 2, 2026 |
| Estimated Study Completion Date : | November 2, 2026 |
Keynote 10.12 6 7
Keynote 10.12 6 Pro
Keynote Download For Mac 10.12.6
